CMV in hematopoietic stem cell transplantation

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 8, Issue 1, 2016, Pages

  Cámara, Rafael de la ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BENZIMIDAVIR; BRINCIDOFOVIR; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; LETERMOVIR; PLACEBO; VALGANCICLOVIR;

ACUTE MYELOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTIVIRAL THERAPY; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEALTH CARE NEED; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LEUKEMIA RELAPSE; LUNG LAVAGE; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SERODIAGNOSIS; SEROPREVALENCE; VIREMIA; VIRUS DETECTION; VIRUS LOAD; VIRUS PNEUMONIA; VIRUS REPLICATION;

EID: 84976487763     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/mjhid.2016.031     Document Type: Review

References (107)

1. Rifkind D. Cytomegalovirus infection after renal transplantation. Arch Intern Med. 1965;116(4):554-8. http://dx.doi.org/10.1001/archinte.1965.03870040068014 PMid:4284275
2. Petersen EA. Extrapulmonary cytomegalovirus disease in transplant patients. Transplant-Proc. 1991;23(2 Suppl 1):13-6. PMid:1647557
3. Balfour HH, Jr. Cytomegalovirus: the troll of transplantation. Arch Intern Med. 1979;139(3):279-80. http://dx.doi.org/10.1001/archinte.1979.03630400011006
4. Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. The Lancet infectious diseases. 2011;11(4):284-92. http://dx.doi.org/10.1016/S1473-3099(11)70024-X
5. Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369(13):1227-36. http://dx.doi.org/10.1056/NEJMoa1303688 PMid:24066743
6. Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M, Groth C, et al. Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation. New England Journal of Medicine. 2014;370(19):1781-9. http://dx.doi.org/10.1056/NEJMoa1309533
7. Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Annals of Internal Medicine. 2015;162(1):1-10. http://dx.doi.org/10.7326/M13-2729 PMid:25560711 PMCid:PMC4465336
8. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. New England Journal of Medicine. 2010;363(22):2091-101. http://dx.doi.org/10.1056/NEJMoa1004383 PMid:21105791 PMCid:PMC3017343
9. Green ML, Leisenring W, Stachel D, Pergam SA, Sandmaier BM, Wald A, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(11):1687-99. http://dx.doi.org/10.1016/j.bbmt.2012.05.015 PMid:22683614 PMCid:PMC3467354
10. Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91(1):78-83. PMid:16434374
11. Pinana JL, Martino R, Barba P, Margall N, Roig MC, Valcarcel D, et al. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. Bone Marrow Transplant. 2010;45(3):534-42. http://dx.doi.org/10.1038/bmt.2009.180 PMid:19668235
12. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, et al. Polymerase chain reaction monitoring reduces the incidence of CMV disease and the duration and side effects of antiviral therapy after BMT. Blood. 1995;86(7):2815-20. PMid:7670117
13. Walker CM, van Burik JA, De For TE, Weisdorf DJ. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant. 2007;13(9):1106-15. http://dx.doi.org/10.1016/j.bbmt.2007.06.006 PMid:17697973
14. Mori T, Mori S, Kanda Y, Yakushiji K, Mineishi S, Takaue Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33(4):431-4. http://dx.doi.org/10.1038/sj.bmt.1704369 PMid:14676775
15. Jang Eä, Park SY, Lee EJ, Song EH, Chong YP, Lee Sä, et al. Diagnostic Performance of the Cytomegalovirus (CMV) Antigenemia Assay in Patients with CMV Gastrointestinal Disease. Clinical Infectious Diseases. 2009;48(12):e121-e4.
16. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101(2):407-14. http://dx.doi.org/10.1182/blood-2002-03-0993 PMid:12393659
17. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122(23):3843-4. http://dx.doi.org/10.1182/blood-2013-10-531103 PMid:24288410
18. von Hofsten J, Johnsson Forsberg M, Zetterberg M. Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib. N Engl J Med. 2016;374(3):296-7. http://dx.doi.org/10.1056/NEJMc1413918 PMid:26789901
19. EMA reviews cancer medicine Zydelig. 11 March 2016 [press release]. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2016/03/WC500203235.pdf, 11 March 2016 2016.
20. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062-8. http://dx.doi.org/10.1038/leu.2015.212
21. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34(8):1094-7. http://dx.doi.org/10.1086/339329 PMid:11914998
22. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711-9. http://dx.doi.org/10.1182/blood-2008-10-143560 PMid:19299333 PMCid:PMC2700312
23. Hohenthal U, Itala M, Salonen J, Sipila J, Rantakokko-Jalava K, Meurman O, et al. Bronchoalveolar lavage in immunocompromised patients with haematological malignancy-value of new microbiological methods. Eur J Haematol. 2005;74(3):203-11. http://dx.doi.org/10.1111/j.1600-0609.2004.00373.x PMid:15693789
24. Cathomas G, Morris P, Pekle K, Cunningham I, Emanuel D. Rapid diagnosis of cytomegalovirus pneumonia in marrow transplant recipients by bronchoalveolar lavage using the polymerase chain reaction, virus culture, and the direct immunostaining of alveolar cells. Blood. 1993;81(7):1909-14. PMid:7681706
25. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;31(16):1006-10. http://dx.doi.org/10.1056/NEJM198604173141602 PMid:3007984
26. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86(9):3598-603. PMid:7579469
27. Schmidt GM, Horak DA, Niland J, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991;324(15):1005-11. http://dx.doi.org/10.1056/NEJM199104113241501 PMid:1848679
28. Goodrich JM, Mori M, Gleaves CA, Mond CD, Cays M, Ebling DF, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325(23):1601-7. http://dx.doi.org/10.1056/NEJM199112053252303 PMid:1658652
29. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118(3):179-84. http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00004 PMid:8380243
30. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Inter Med. 1993;118(3):173-8. http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00003
31. Rubin RH. Preemptive therapy in immunocompromised hosts [editorial; comment]. N-Engl-J-Med. 1991;324(15):1057-9. http://dx.doi.org/10.1056/NEJM199104113241509 PMid:1848680
32. Humar A, Lipton J, Welsh S, Moussa G, Messner H, Mazzulli T. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Bone Marrow Transplant. 2001;28(5):485-90. http://dx.doi.org/10.1038/sj.bmt.1703178 PMid:11593322
33. Bratanow NC, Ash RC, Turner PA, Smith R, Haasler G, Chitambar C, et al. Successful treatment of serious cytomegalovirus disease with 9(1,3-dihydroxy-2-propoxymethyl)-guanine and intravenous immunoglobulin in bone marrow transplant patients. Exp Hematol. 1987;15(70 (suppl 1)):541(abstract 254).
34. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988;109(10):783-8. http://dx.doi.org/10.7326/0003-4819-109-10-783 PMid:2847610
35. Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109(10):777-82. http://dx.doi.org/10.7326/0003-4819-109-10-777 PMid:2847609
36. Schmidt GM, Kovacs A, Zaia JA, Horak DA, Blume KG, Nademanee AP, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation. http://dx.doi.org/10.1097/00007890-198812000-00022
37. Ljungman P, Engelhard D, Link H, Biron P, Brandt L, Brunet S, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis. 1992;14(4):831-5. http://dx.doi.org/10.1093/clinids/14.4.831 PMid:1315585
38. Shepp DH, Dandliker PS, de Miranda P, Burnette TC, Cederberg DM, Kirk LE, et al. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Inter Med. 1985;103(3):368-73. http://dx.doi.org/10.7326/0003-4819-103-3-368
39. Reed EC, Dandliker PS, Meyers JD. Treatment of cytomegalovirus pneumonia with 9-[2-hydroxy-1- (hydroxymethyl)ethoxymethyl]guanine and high-dose corticosteroids. Ann Inter Med. 1986;105(2):214-5. http://dx.doi.org/10.7326/0003-4819-105-2-214
40. Winston DJ, Ho WG, Bartoni K, Holland GN, Mitsuyasu RT, Gale RP, et al. Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev Infect Dis. 1988;10 Suppl 3(3):S547-53.
41. Erice A, Jordan MC, Chace BA, Fletcher C, Chinnock BJ, Balfour HH, Jr. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA. 1987;257(22):3082-7. http://dx.doi.org/10.1001/jama.1987.03390220080025 PMid:3035246
42. Ringden O, Wilczek H, Lonnqvist B, Gahrton G, Wahren B, Lernestedt JO. Foscarnet for cytomegalovirus infections. Lancet. 1985;1(8444):1503-4. http://dx.doi.org/10.1016/S0140-6736(85)92272-X
43. Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood. 1994;83(9):2392-8. PMid:8167329
44. Reed EC. Treatment of cytomegalovirus pneumonia in transplant patients. Transplant Proc. 1991;23(2 Suppl 1):8-12. PMid:1647562
45. Reed EC, Wolford JL, Kopecky KJ, Lilleby KE, Dandliker PS, Todaro JL, et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med. 1990;112(7):505-10. http://dx.doi.org/10.7326/0003-4819-112-7-505 PMid:2156476
46. Erard V, Guthrie KA, Seo S, Smith J, Huang M, Chien J, et al. Reduced Mortality of Cytomegalovirus Pneumonia after Hematopoietic Cell Transplantation Due To Antiviral Therapy and Changes in Transplantation Practices. Clinical Infectious Diseases. 2015;61(1):31-9. http://dx.doi.org/10.1093/cid/civ215 PMid:25778751
47. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358-66. http://dx.doi.org/10.1182/blood-2002-05-1496 PMid:12393425
48. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of Invasive Mold Infections in Allogeneic Stem Cell Transplant Recipients: Biological Risk Factors for Infection According to Time after Transplantation. Clinical Infectious Diseases. 2008;47(8):1041-50. http://dx.doi.org/10.1086/591969 PMid:18781877 PMCid:PMC2668264
49. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181(1):309-16. http://dx.doi.org/10.1086/315193 PMid:10608780
50. Jain NA, Lu K, Ito S, Muranski P, Hourigan CS, Haggerty J, et al. The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches. Cytotherapy. 2014;16(7):927-33. http://dx.doi.org/10.1016/j.jcyt.2014.02.010 PMid:24831837 PMCid:PMC4051841
51. Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V, et al. Increased transplant-related morbidity and mortality in CMV- seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95(7):2240-5. PMid:10733491
52. Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(9):1309-14. http://dx.doi.org/10.1016/j.bbmt.2010.03.020 PMid:20353832
53. Paulin T, Ringden O, Nilsson B, Lonnqvist B, Gahrton G. Variables predicting bacterial and fungal infections after allogeneic marrow engraftment. Transplantation. 1987;43(3):393-8. http://dx.doi.org/10.1097/00007890-198703000-00015 PMid:3029908
54. Tollemar J, Ringden O, Bostrom L, Nilsson B, Sundberg B. Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 1989;4(6):635-41. PMid:2555004
55. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185(3):273-82. http://dx.doi.org/10.1086/338624 PMid:11807708
56. Humar A, Wood S, Lipton J, Messner H, Meharchand J, McGeer A, et al. Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants Clin Infect Dis. 1998;26(3):606-10. http://dx.doi.org/10.1086/514569 PMid:9524831
57. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115(20):4715-26. http://dx.doi.org/10.1002/cncr.24531 PMid:19642176
58. Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis. Blood. 2016. http://dx.doi.org/10.1182/blood-2015-11-679639 PMid:26884374
59. Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, et al. Donor Cytomegalovirus Status Influences the Outcome of Allogeneic Stem Cell Transplant: A Study by the European Group for Blood and Marrow Transplantation. Clinical Infectious Diseases. 2014;59(4):473-81. http://dx.doi.org/10.1093/cid/ciu364 PMid:24850801
60. Nemeckova S, Sroller V, Stastna-Markova M. Evolution of human cytomegalovirus-seronegative donor/-seropositive recipient high-risk combination frequency in allogeneic hematopoietic stem cell transplantations at Institute of Hematology and Blood Transfusion during 1995-2014. Transplant Infectious Disease. 2016;18(2):297-301. http://dx.doi.org/10.1111/tid.12508 PMid:26858009
61. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis. 2006;43(9):1143-51. http://dx.doi.org/10.1086/508173 PMid:17029132
62. Pasquini M, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: CIBMTR Summary Slides 2015 [Available from: http://www.cibmtr.org .
63. Gale RP, Seber A, Bonfim C, Pasquini M. Haematopoietic cell transplants in Latin America. Bone Marrow Transplant. 2016. http://dx.doi.org/10.1038/bmt.2016.35
64. Lonnqvist B, Ringden O, Ljungman P, Wahren B, Gahrton G. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol. 1986;63(4):671-9. http://dx.doi.org/10.1111/j.1365-2141.1986.tb07551.x PMid:3015193
65. Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M, et al. Early human cytomegalovirus replication after transplant is associated with a decreased relapse-risk: evidence for a putative virus-versus-leukemia effect AML patients. Blood. 2011;118(5):1402-12. http://dx.doi.org/10.1182/blood-2010-08-304121 PMid:21540462
66. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98(7):2043-51. http://dx.doi.org/10.1182/blood.V98.7.2043 PMid:11567988
67. Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013;122(19):3359-64. http://dx.doi.org/10.1182/blood-2013-05-499830
68. Ljungman P, de la Camara R, Cordonnier C, Einsele H, Engelhard D, Reusser P, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 2008;42(4):227-40. http://dx.doi.org/10.1038/bmt.2008.162
69. Zaia J, Baden L, Boeckh MJ, Chakrabarti S, Einsele H, Ljungman P, et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44(8):471-82. http://dx.doi.org/10.1038/bmt.2009.258 PMid:19861981
70. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99(4):1159-64. http://dx.doi.org/10.1182/blood.V99.4.1159 PMid:11830461
71. Reddy SM, Winston DJ, Territo MC, Schiller GJ. CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency. Bone Marrow Transplant. 2010;45(6):979-84. http://dx.doi.org/10.1038/bmt.2010.35 PMid:20190836
72. Maffini E, Giaccone L, Festuccia M, Brunello L, Busca A, Bruno B. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. 2016:1-12. http://dx.doi.org/10.1080/17474086.2016.1174571
73. Boeckh M, Murphy WJ, Peggs KS. Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant. 2015;21(1):24-9. http://dx.doi.org/10.1016/j.bbmt.2014.11.002 PMid:25452035
74. Machado CM, Dulley FL, Boas LS, Castelli JB, Macedo MC, Silva RL, et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant. 2000;26(4):413-7. http://dx.doi.org/10.1038/sj.bmt.1702526 PMid:10982288
75. Battiwalla M, Wu Y, Bajwa RP, Radovic M, Almyroudis NG, Segal BH, et al. Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant. 2007;13(7):765-70. http://dx.doi.org/10.1016/j.bbmt.2007.03.009 PMid:17580254
76. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997;90(6):2502-8. PMid:9310503
77. Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 2000;25(7):757-63. http://dx.doi.org/10.1038/sj.bmt.1702226 PMid:10745262
78. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34(2):115-21. http://dx.doi.org/10.1038/sj.bmt.1704543 PMid:15156166
79. Larsson K, Aschan J, Remberger M, Ringden O, Winiarski J, Ljungman P. Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus. Transplantation. 2004;77(4):526-31. http://dx.doi.org/10.1097/01.TP.0000109778.39235.F4 PMid:15084929
80. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied N, Fernandez Ranada JM, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet. 1994;343(8900):749-53. http://dx.doi.org/10.1016/S0140-6736(94)91835-X
81. Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, Vicary CA, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988;318(2):70-5. http://dx.doi.org/10.1056/NEJM198801143180202 PMid:2827025
82. Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers ME, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus (VZV) disease following hematopoietic cell transplantation: no evidence of rebound VZV disease after drug discontinuation. Blood. 2007;110(8):3071-7. http://dx.doi.org/10.1182/blood-2007-03-077644 PMid:17515400
83. Ljungman P, de la Camara R, Milpied N, Volin L, Russell CA, Crisp A, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 2002;99(8):3050-6. http://dx.doi.org/10.1182/blood.V99.8.3050 PMid:11929799
84. Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis. 2003;36(6):749-58. http://dx.doi.org/10.1086/367836 PMid:12627359
85. Palladino M, Laurenti L, Chiusolo P, Piccioni P, Innocenti I, Tarnani M, et al. Low-Dose Valganciclovir as Preemptive Therapy for Cytomegalovirus Infection Occurring in Allogeneic Stem Cell Transplant Recipients. Acta Haematologica. 2010;123(4):230-4. http://dx.doi.org/10.1159/000313639 PMid:20424437
86. Solano C, Munoz-Cobo B, Gimenez E, Remigia MJ, Amat P, Clari MA, et al. Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center. Bone Marrow Transplant. 2013;48(7):1010-2. http://dx.doi.org/10.1038/bmt.2012.286 PMid:23334275
87. George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis. 2010;12(4):322-9. http://dx.doi.org/10.1111/j.1399-3062.2010.00504.x PMid:20487414
88. Shmueli E, Or R, Shapira MY, Resnick IB, Caplan O, Bdolah-Abram T, et al. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis. 2014;209(4):557-61. http://dx.doi.org/10.1093/infdis/jit475 PMid:23983215
89. Furione M, Rognoni V, Cabano E, Baldanti F. Kinetics of human cytomegalovirus (HCMV) DNAemia in transplanted patients expressed in international units as determined with the Abbott RealTime CMV assay and an in-house assay. J Clin Virol. 2012;55(4):317-22. http://dx.doi.org/10.1016/j.jcv.2012.08.017 PMid:22989927
90. Ugarte-Torres A, Hoegh-Petersen M, Liu Y, Zhou F, Williamson TS, Quinlan D, et al. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2011;17(4):574-85. http://dx.doi.org/10.1016/j.bbmt.2010.07.020 PMid:20688181
91. Solano C, de la Camara R, Vazquez L, Lopez J, Gimenez E, Navarro D. Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain. J Clin Microbiol. 2015;53(8):2741-4. http://dx.doi.org/10.1128/JCM.01057-15 PMid:26063857 PMCid:PMC4508446
92. X. L. Pang JDF, J. M. Fenton, G. G. Miller, A. M. Caliendo, J. K. Preiksaitis,. Interlaboratory Comparison of Cytomegalovirus Viral Load Assays. American Journal of Transplantation. 2009;9(2):258-68. http://dx.doi.org/10.1111/j.1600-6143.2008.02513.x PMid:19178413
93. Fryer JF, Heath AB, Anderson R, Minor PD, and the collaborative study group. Collaborative study to evaluate the proposed 1st WHO International Standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. WHO ECBS Report. 2010;WHO/BS/10.2138.: http://www.nibsc.org/PDF/HCMV_IS.pdf
94. Griffiths PD. Of London buses and the treatment of cytomegalovirus infection. Rev Med Virol. 2014;24(4):221-2. http://dx.doi.org/10.1002/rmv.1800 PMid:24889066
95. Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263. Drugs R D. 2007;8(3):188-92. http://dx.doi.org/10.2165/00126839-200708030-00006 PMid:17472414
96. Florescu DF, Pergam SA, Neely MN, Qiu F, Johnston C, Way S, et al. Safety and Efficacy of CMX001 as Salvage Therapy for Severe Adenovirus Infections in Immunocompromised Patients. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2012;18(5):731-8. http://dx.doi.org/10.1016/j.bbmt.2011.09.007
97. Verghese PS, Schleiss MR. Letermovir. Drugs of the Future. 2013;38(5):291-8. http://dx.doi.org/10.1358/dof.2013.038.05.1946425
98. Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111(11):5403-10. http://dx.doi.org/10.1182/blood-2007-11-121558 PMid:18285548
99. Marty F, Winston D, Chemaly RF, Boeckh M, Mullane K, Shore D, et al. Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell transplantation (HCT in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial. BMT Tandem Meeting; February 20, 2016; Honululu, Hawai2016.
100. Snydman DR. Why did maribavir fail in stem-cell transplants? The Lancet Infectious Diseases. 2011;11(4):255-7. http://dx.doi.org/10.1016/S1473-3099(11)70033-0
101. Alain S, Revest M, Veyer D, Essig M, Rerolles JP, Rawlinson W, et al. Maribavir Use in Practice for Cytomegalovirus Infection in French Transplantation Centers. Transplantation proceedings. 2013;45(4):1603-7. http://dx.doi.org/10.1016/j.transproceed.2013.01.082 PMid:23726629
102. Avery RK, Marty FM, Strasfeld L, Lee I, Arrieta A, Chou S, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transplant Infectious Disease. 2010;12(6):489-96. http://dx.doi.org/10.1111/j.1399-3062.2010.00550.x PMid:20682012
103. Grimley M, Papanicolaou G, Maron G, Chittick G, Brundage T, Bae A, et al. Improved Outcomes in Allogeneic Hematopoietic Cell Transplant Patients Treated with Brincidofovir (CMX001, BCV) for Disseminated Adenovirus Disease Compared to Literature. Bone Marow Transplant. 2015;50(suppl 1):S29, abstract 049.
104. Karniely S, Weekes MP, Antrobus R, Rorbach J, van Haute L, Umrania Y, et al. Human Cytomegalovirus Infection Upregulates the Mitochondrial Transcription and Translation Machineries. MBio. 2016;7(2). http://dx.doi.org/10.1128/mBio.00029-16 PMid:27025248 PMCid:PMC4807356
105. McVoy MA. Cytomegalovirus Vaccines. Clinical Infectious Diseases. 2013;57(suppl 4):S196-S9. http://dx.doi.org/10.1093/cid/cit587 PMid:24257427 PMCid:PMC3836572
106. Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(4):290-9. http://dx.doi.org/10.1016/S1473-3099(11)70344-9
107. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, Chehata S, Esperou H, Vernant JP, Michallet M, Buzyn A, Gratecos N, Cahn JY, Bourhis JH, Chir Z, Raffoux C, Socie G, Golmard JL, Jouet JP. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24(36):5695-702 http://dx.doi.org/10.1200/JCO.2006.08.0952